from the quickly evolving area of oncology investigate, correct and effective mutation screening is essential for acquiring specific therapies. The KRAS products and services Platform plays a pivotal role On this landscape by offering complete methods for KRAS mutation profiling and analysis. KRAS mutations, located in somewhere around ninety five%